Cambridge Healthtech Institute's Twentieth Annual

Recombinant Protein Expression and Production

( 重组蛋白质的表现与生产 )

Achieving Quality and Quantity

2018年1月9日 - 10日


Biopharmaceuticals currently represent the fastest-growing sector of the pharmaceutical industry, driven by a rapid expansion in the manufacture of recombinant protein-based drugs. Consequently, the efficient expression and production of these valuable biomolecules face challenges in improving their quantity and quality while minimizing time and cost. To meet these demands, an increasing variety of recombinant production platforms are being developed. Unfortunately, there is no "universal" production system which can guarantee high yields of recombinant protein, particularly as every biomolecule itself causes its own issues in terms of expression. To meet the demand, it is crucial to increase the throughput of expression, production and purification processes and systems.

Cambridge Healthtech Institute's Recombinant Protein Expression and Production conference explores the newest data and innovations relating to the best choices in hosts/systems, as well as ways to "rescue" existing systems and make them work more effectively to produce the quality and quantity of the desired biotherapeutic.

Preliminary Agenda


Overexpression of Ebola Virus Envelope GP1 Protein

Zhongcheng Zou, Ph.D., Staff Scientist, Structural Immunology Section, Lab of Immunogenetics, NIAID/NIH

Redirecting Bacterial Microcompartment Systems to Improve Expression of Toxic Proteins

Mimi Cho Yung, Ph.D. Biomedical Staff Scientist, Biosciences and Biotechnology Division, Lawrence Livermore National Laboratory

Using GlycoExpress to Overcome Production Limitations for Difficult-to-Express Proteins

Rainer Stahn, Ph.D., Director, Process Development, Glycotope


Super Secretory Production of Recombinant Antibody Fragments by Precisely Controlled Fed-Batch Culture of E. coli

Yoichi Kumada, Dr. Eng., Associate Professor, Kyoto Institute of Technology


Optimizing Expression of Proteins in CHO through a Systems Biology Approach

Nathan E. Lewis, Ph.D., Assistant Professor, Department of Pediatrics, University of California, San Diego

Expression of Recombinant Blood Coagulation Factor VIII: Importance for Human Healthcare and Approaches to Improve the Protein's Yield and Quality

Andrey G. Sarafanov, Ph.D., Chemist, Principal Investigator, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration (FDA)

Protein Production Platform for Rational Design Engineering

Takanori Kigawa, Ph.D., Team Leader, Quantitative Biology Center, RIKEN


Membrane Protein Production and Characterization in Tailored Lipid Environments

Daniel Foshag, Ph.D., Postdoctoral Researcher, Institute of Biophysical Chemistry, Goethe University Frankfurt

* 活动内容有可能不事先告知作更动及调整。